Literature DB >> 27881157

Plasma microRNAs are associated with acute exacerbation in idiopathic pulmonary fibrosis.

Haiyan Min1,2, Shanshan Fan2, Shiyu Song2, Yi Zhuang1, Hui Li1, Yongzheng Wu2, Hourong Cai1, Long Yi2, Jinghong Dai3, Qian Gao4.   

Abstract

BACKGROUND: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) has high short-term mortality with unknown causes. To predict this malignant condition in clinics is challenging. In this study, we aim to demonstrate whether there are miRNAs that differ between AE-IPF and stable IPF, which may be served as reliable biomarker for AE-IPF prediction.
METHODS: Human fibrotic-associated miRNAs arrays were designed to detect miRNAs expression in plasma of 3 AE-IPF patients, 3 Stable-IPF (S-IPF) patients and 3 normal controls (NC). Differentially expressed miRNAs between AE-IPF and S-IPF patients were selected for further analyses. The validation studies were carried out in plasma of 12 AE-IPF patients, 45 S-IPF patients and 51 healthy control subjects. Signaling pathways and cellular processes interacted with validated miRNAs were predicted by DIANA-miRPath.
RESULTS: According to the array analysis, 6 miRNAs showed differentiated expression between AE-IPF and S-IPF patients (P < 0.05). In the validation studies, let-7d-5p was decreased in S-IPF and further decreased in AE-IPF, when compared to NC (0.0003 ± 0.0002 vs 0.003 ± 0.002, P < 0.01 and 0.0007 ± 0.0005 vs 0.003 ± 0.002, P < 0.01). While miR-25-3p was obviously decreased in S-IPF (0.0002 ± 0.0001 vs 0.0003 ± 0.0003, P < 0.01) but significantly increased in AE-IP (0.0023 ± 0.002 vs 0.0003 ± 0.0003, P < 0.01). In receiver-operator characteristic (ROC) curve analysis, the areas under the curve (AUCs) of miR-25-3p and let-7d-5p were 0.83 and 0.75, respectively. The sensitivity at fixed specificity of 90% was improved from 50% to 66.7% when the two miRNAs were combined. The functional prediction of miRNAs suggested that the loss of anti-fibrotic capacity and the gain of uncontrolled cell growth may be required in AE-IPF pathogenesis.
CONCLUSIONS: In conclusion, miR-25-3p and let-7d-5p in plasma were differentially expressed between AE-IPF and S-IPF. A combination of these two miRNAs may be a potential biomarker for AE-IPF from IPF.

Entities:  

Keywords:  Acute exacerbation; Idiopathic pulmonary fibrosis; let-7d-5p; miR-25-3p

Mesh:

Substances:

Year:  2016        PMID: 27881157      PMCID: PMC5120520          DOI: 10.1186/s13000-016-0583-2

Source DB:  PubMed          Journal:  Diagn Pathol        ISSN: 1746-1596            Impact factor:   2.644


  31 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression.

Authors:  Guanghai Yang; Lin Yang; Wendong Wang; Jiashun Wang; Jianjun Wang; Zhongping Xu
Journal:  Gene       Date:  2015-02-25       Impact factor: 3.688

3.  Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma.

Authors:  Li-Min Li; Zhi-Bin Hu; Zhen-Xian Zhou; Xi Chen; Fen-Yong Liu; Jun-Feng Zhang; Hong-Bing Shen; Chen-Yu Zhang; Ke Zen
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

4.  Telomerase gene mutations and telomere length shortening in patients with idiopathic pulmonary fibrosis in a Chinese population.

Authors:  Jinghong Dai; Hourong Cai; Yi Zhuang; Yongzheng Wu; Haiyan Min; Jinheng Li; Yi Shi; Qian Gao; Long Yi
Journal:  Respirology       Date:  2014-10-23       Impact factor: 6.424

5.  Inhibition and role of let-7d in idiopathic pulmonary fibrosis.

Authors:  Kusum V Pandit; David Corcoran; Hanadie Yousef; Manohar Yarlagadda; Argyris Tzouvelekis; Kevin F Gibson; Kazuhisa Konishi; Samuel A Yousem; Mandal Singh; Daniel Handley; Thomas Richards; Moises Selman; Simon C Watkins; Annie Pardo; Ahmi Ben-Yehudah; Demosthenes Bouros; Oliver Eickelberg; Prabir Ray; Panayiotis V Benos; Naftali Kaminski
Journal:  Am J Respir Crit Care Med       Date:  2010-04-15       Impact factor: 21.405

6.  MicroRNA-25 promotes gastric cancer migration, invasion and proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor survival.

Authors:  B-S Li; Q-F Zuo; Y-L Zhao; B Xiao; Y Zhuang; X-H Mao; C Wu; S-M Yang; H Zeng; Q-M Zou; G Guo
Journal:  Oncogene       Date:  2014-07-21       Impact factor: 9.867

7.  MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer.

Authors:  X Wang; X Meng; H Li; W Liu; S Shen; Z Gao
Journal:  Clin Transl Oncol       Date:  2014-04-03       Impact factor: 3.405

8.  A micro RNA processing defect in rapidly progressing idiopathic pulmonary fibrosis.

Authors:  Sameer R Oak; Lynne Murray; Athula Herath; Matthew Sleeman; Ian Anderson; Amrita D Joshi; Ana Lucia Coelho; Kevin R Flaherty; Galen B Toews; Darryl Knight; Fernando J Martinez; Cory M Hogaboam
Journal:  PLoS One       Date:  2011-06-21       Impact factor: 3.240

9.  Inflammatory leukocyte phenotypes correlate with disease progression in idiopathic pulmonary fibrosis.

Authors:  Bethany B Moore; Chris Fry; Yueren Zhou; Susan Murray; MeiLan K Han; Fernando J Martinez; Kevin R Flaherty
Journal:  Front Med       Date:  2014-12-22       Impact factor: 4.592

10.  Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis.

Authors:  Tasha E Fingerlin; Elissa Murphy; Weiming Zhang; Anna L Peljto; Kevin K Brown; Mark P Steele; James E Loyd; Gregory P Cosgrove; David Lynch; Steve Groshong; Harold R Collard; Paul J Wolters; Williamson Z Bradford; Karl Kossen; Scott D Seiwert; Roland M du Bois; Christine Kim Garcia; Megan S Devine; Gunnar Gudmundsson; Helgi J Isaksson; Naftali Kaminski; Yingze Zhang; Kevin F Gibson; Lisa H Lancaster; Joy D Cogan; Wendi R Mason; Toby M Maher; Philip L Molyneaux; Athol U Wells; Miriam F Moffatt; Moises Selman; Annie Pardo; Dong Soon Kim; James D Crapo; Barry J Make; Elizabeth A Regan; Dinesha S Walek; Jerry J Daniel; Yoichiro Kamatani; Diana Zelenika; Keith Smith; David McKean; Brent S Pedersen; Janet Talbert; Raven N Kidd; Cheryl R Markin; Kenneth B Beckman; Mark Lathrop; Marvin I Schwarz; David A Schwartz
Journal:  Nat Genet       Date:  2013-04-14       Impact factor: 38.330

View more
  6 in total

Review 1.  The role of microRNAs in chronic respiratory disease: recent insights.

Authors:  Lindsay R Stolzenburg; Ann Harris
Journal:  Biol Chem       Date:  2018-02-23       Impact factor: 3.915

2.  Analysis of the Interaction Network of Hub miRNAs-Hub Genes, Being Involved in Idiopathic Pulmonary Fibers and Its Emerging Role in Non-small Cell Lung Cancer.

Authors:  Dong Hu Yu; Xiao-Lan Ruan; Jing-Yu Huang; Xiao-Ping Liu; Hao-Li Ma; Chen Chen; Wei-Dong Hu; Sheng Li
Journal:  Front Genet       Date:  2020-04-02       Impact factor: 4.599

Review 3.  The function of non-coding RNAs in idiopathic pulmonary fibrosis.

Authors:  Hui Zhang; Miao Song; Jianing Guo; Junbing Ma; Min Qiu; Zheng Yang
Journal:  Open Med (Wars)       Date:  2021-03-26

Review 4.  Exosomes in pathogenesis, diagnosis, and treatment of pulmonary fibrosis.

Authors:  Yang Yang; Yufei Liu; Yilu Chai; Ke Liu; Wei Hu; Keni Zhao; Yi Zhu; Peiyang Gao; Qingsong Huang; Chuantao Zhang
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

Review 5.  Roles of exosomes and exosome-derived miRNAs in pulmonary fibrosis.

Authors:  Yongfeng Yang; Hong Huang; Yi Li
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

6.  MicroRNA 3113-5p is a novel marker for early cardiac ischemia/reperfusion injury.

Authors:  Yuanyuan Chen; Xing Ye; Fengping Yan
Journal:  Diagn Pathol       Date:  2019-10-31       Impact factor: 2.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.